Preferred options for the treatment of comorbidities are GLP-1 RAs, tirzepatide (dual GIP/GLP-1 RA), SGLT2is, metformin or insulin (in case of decompensated cirrhosis) for T2D; statins for dyslipidemia; and GLP-1 RAs, tirzepatide (dual GIP/GLP-1 RA) for obesity [83]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.